LA JOLLA PHARMACEUTICAL CO
LJPC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LJPC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Market Cap
—
Cash Runway
—
Lead Asset
giapreza (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2022.
Tracking 2 pipeline candidates for LA JOLLA PHARMACEUTICAL CO.
Run LA JOLLA PHARMACEUTICAL CO through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available LA JOLLA PHARMACEUTICAL CO facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
Profitable (positive operating cash flow)
OCF $7M · Net income $2M
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is LA JOLLA PHARMACEUTICAL CO's lead drug candidate?
LA JOLLA PHARMACEUTICAL CO's most advanced tracked candidate is giapreza (Approved) for septic or other distributive shock.
Who is the CEO of LA JOLLA PHARMACEUTICAL CO?
Larry Edwards is the chief executive officer of LA JOLLA PHARMACEUTICAL CO (LJPC).
What therapeutic areas does LA JOLLA PHARMACEUTICAL CO focus on?
LA JOLLA PHARMACEUTICAL CO develops therapies across Oncology, Immunology, Infectious Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.